Advanced Filters
noise

vascular-diseases Clinical Trials

A listing of vascular-diseases medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 859 clinical trials
A Aurélien Delluc, M.D. Ph. D.

Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism

Venous thromboembolism (VTE) can be the earliest sign of cancer. Identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care. This is also an upmost issue for patients who want to know if an underlying cancer might have triggered the VTE. An individual …

50 years of age All Phase N/A
L Laurence Bouillet, MD, PhD

CLOUD-R HAE REGISTRY

Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. In this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. Attacks can appear as part of the …

years of age All Phase N/A
O Olivier HANON, MD, PhD

Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals

The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.

60 - 88 years of age All Phase 4
N Naveed Majeed, MD, MS

SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry

Prospective, international, single-arm, multicenter, registry study. Patients presenting with evidence of Wide Neck unruptured or ruptured intracranial aneurysm (≤ 20 mm in widest diameter) requiring treatment will be enrolled into the study and treated using the SEAL™ System.

18 - 80 years of age All Phase N/A
C Chen Yu, MD

Application of QDSA Platform in Cerebrovascular Diseases

Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a …

1 - 80 years of age All Phase N/A
F Francesca Cecchi, MD

National Database of the Virtual Institute of Cerebrovascular Diseases

The overall objective of the study is to identify prognostic predictors of cerebrovascular disease during various stages of the cerebrovascular disease itself, namely: hospitalization at the acute care facility, residential hospitalization at neurorehabilitation facilities, outpatient follow-up visits, and day hospital admissions at the various facilities. The aim is to obtain …

years of age All Phase N/A
T Theodoros Kratimenos, Dr

Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis

The goal of this observational study is to collect mid-term post-market clinical follow-up data of GORE® TAG® Thoracic Branch Endoprosthesis used according to the standard medical practice in patients presenting with vascular disease. This registry aims to answer questions related to the efficacy and safety of GORE® TAG® Thoracic Branch …

18 years of age All Phase N/A
B Byeong-Keuk Kim

Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial

Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.

19 - 84 years of age All Phase N/A
H Hyeon-Cheol Gwon, Professor

GENOSS Coronary Stent Clinical Trial

This study aims to evaluate the efficacy and safety of abluminal biodegradable polymer ultrathin sirolimus-eluting stent (Genoss stent) as compared with a durable-polymer everolimus-eluting stent (Xience stent) in patients with coronary artery disease.

19 years of age All Phase N/A
H Henning Bundgaard, MD, DMSci

Clinical Implementation of a Novel Decision Support Tool in Patients With Ischemic Heart Disease

The PM-Heart algorithm (PMHeartIHD) is an in-house developed software that predict the survival prognosis for the individual patient hospitalized with ischemic heart disease (IHD) after a coronary arteriography has been performed. The software is intended to be used as a clinical decision support system i.e. the calculated survival prognosis is …

18 years of age All Phase N/A

Simplify language using AI